Acetyl-CoA synthetase 2 (ACSS2; involved in β-oxidation) expression is increased in MM patients (67) and inhibition of β-oxidation with Etomoxir (a CPT1 inhibitor) and/or Orlistat (a Fatty acid synthase (FASN) inhibitor), decreased MM proliferation (68). Here, FASN is linked to Miyoshi myopathy.